MedWatch

Wegovy weight loss results "very encouraging," says Novo EVP

Recently launched weight loss drug Wegovy has reportedly shown an average loss of weight of 15.2 percent over two years in a phase IIIb trial. This is "very encouraging," says EVP Martin Holst Lange.

Photo: Tidsvilde Stine/Ritzau Scanpix

An average weight loss of 15.2 percent over two years. These results come from a phase IIIb study of the obesity drug Wegovy, Novo Nordisk reports in a press release in connection with this year's Obesity Week.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs